Your browser doesn't support javascript.
loading
Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial.
Michallet, Anne-Sophie; Dilhuydy, Marie-Sarah; Subtil, Fabien; Rouille, Valerie; Mahe, Beatrice; Laribi, Kamel; Villemagne, Bruno; Salles, Gilles; Tournilhac, Olivier; Delmer, Alain; Portois, Christelle; Pegourie, Brigitte; Leblond, Veronique; Tomowiak, Cecile; de Guibert, Sophie; Orsini, Frederique; Banos, Anne; Carassou, Philippe; Cartron, Guillaume; Fornecker, Luc Mathieu; Ysebaert, Loic; Dartigeas, Caroline; Truchan Graczyk, Malgorzata; Vilque, Jean P; Aurran, Thérèse; Cymbalista, Florence; Lepretre, Stéphane; Lévy, Vincent; Nguyen-Khac, Florence; Le Garff-Tavernier, Magali; Aanei, Carmen; Ticchioni, Michel; Letestu, Rémi; Feugier, Pierre.
Affiliation
  • Michallet AS; Department of Hematology, Centre Léon Bérard, Lyon, France. Electronic address: anne-sophie.michallet@lyon.unicancer.fr.
  • Dilhuydy MS; Department of Hematology, CHU Bordeaux, Bordeaux, France.
  • Subtil F; Department of Biostatistics, Hospices Civils de Lyon, Lyon, France.
  • Rouille V; Department of Hematology, CHU Montpellier, Montpellier, France.
  • Mahe B; Department of Hematology, CHU Nantes, Nantes, France.
  • Laribi K; Department of Clinical Hematology, Centre Hospitalier du Mans, Le Mans, France.
  • Villemagne B; Department of Clinical Hematology, CHD Vendee, La Roche sur Yon, France.
  • Salles G; Department of Hematology, Hospices Civils de Lyon, Lyon, France.
  • Tournilhac O; Department of Hematology, CHU Clermont-Ferrand, Clermont-Ferrand, France.
  • Delmer A; Department of Hematology, CHU Reims, Reims, France.
  • Portois C; Department of Hematology, CHU Saint Etienne, Saint Etienne, France.
  • Pegourie B; Department of Hematology, CHU Grenoble, Grenoble, France.
  • Leblond V; Department of Hematology, Assistance Publique Hopitaux de Paris, PitiéSalpêtrière Hospital, Université Paris Sorbonne, Paris, France.
  • Tomowiak C; Department of Hematology, CHU Poitiers, Poitiers, France.
  • de Guibert S; Department of Hematology, CHU Rennes, Rennes, France.
  • Orsini F; Department of Clinical Hematology, Centre Hospitalier Annecy Genevois, Annecy Genevois, France.
  • Banos A; Department of Clinical Hematology, Centre Hospitalier Bayonne, Bayonne, France.
  • Carassou P; Department of Hematology, CHR Metz-Thionville, Metz, France.
  • Cartron G; Department of Hematology, CHU Montpellier, Montpellier, France.
  • Fornecker LM; Department of Hematology, CHU Strasbourg, Strasbourg, France.
  • Ysebaert L; Department of Hematology, CHU Toulouse, Toulouse, France.
  • Dartigeas C; Department of Hematology, CHU Tours, Tours, France.
  • Truchan Graczyk M; Department of Hematology, CHU Angers, Angers, France.
  • Vilque JP; Department of Hematology, CHU Caen, Caen, France.
  • Aurran T; Department of Hematology, Institut Paoli Calmettes, Marseille, Marseille, France.
  • Cymbalista F; Department of Hematology, Avicenne Hospital, Assistance Publique Hopitaux de Paris, Bobigny, France.
  • Lepretre S; Department of Hematology, Centres de Lutte Contre le Cancer Centre Henri-Becquerel, Haute Normandie, Rouen, France.
  • Lévy V; URC/CRC, Avicenne Hospital, Assistance Publique Hopitaux de Paris, Bobigny, France.
  • Nguyen-Khac F; Department of Hematology, Assistance Publique Hopitaux de Paris, PitiéSalpêtrière Hospital, Université Paris Sorbonne, Paris, France.
  • Le Garff-Tavernier M; Department of Hematology Biology, Assistance Publique Hopitaux de Paris, Pitié Salpêtrière, Paris, France.
  • Aanei C; Department of Hematology Biology, CHU Saint Etienne, Saint Etienne, France.
  • Ticchioni M; Department of Immunology, CHU Nice, Nice, France.
  • Letestu R; Department of Hematology Biology, Avicenne Hospital, Assistance Publique Hopitaux de Paris, Bobigny, France.
  • Feugier P; Department of Hematology, CHRU Nancy, Nancy, France.
Lancet Haematol ; 6(9): e470-e479, 2019 Sep.
Article in En | MEDLINE | ID: mdl-31324600
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrazoles / Pyrimidines / Leukemia, Lymphocytic, Chronic, B-Cell / Antineoplastic Combined Chemotherapy Protocols / Antibodies, Monoclonal, Humanized Type of study: Clinical_trials / Etiology_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Lancet Haematol Year: 2019 Document type: Article Country of publication: Reino Unido
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrazoles / Pyrimidines / Leukemia, Lymphocytic, Chronic, B-Cell / Antineoplastic Combined Chemotherapy Protocols / Antibodies, Monoclonal, Humanized Type of study: Clinical_trials / Etiology_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Lancet Haematol Year: 2019 Document type: Article Country of publication: Reino Unido